281 related articles for article (PubMed ID: 31978211)
61. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
62. MYC-associated and double-hit lymphomas: a review of pathobiology, prognosis, and therapeutic approaches.
Petrich AM; Nabhan C; Smith SM
Cancer; 2014 Dec; 120(24):3884-95. PubMed ID: 25060588
[TBL] [Abstract][Full Text] [Related]
63. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma.
Kelly PN; Puthalakath H; Adams JM; Strasser A
Blood; 2007 Jun; 109(11):4907-13. PubMed ID: 17317859
[TBL] [Abstract][Full Text] [Related]
64. N-benzyladriamycin-14-valerate (AD 198) exhibits potent anti-tumor activity on TRAF3-deficient mouse B lymphoma and human multiple myeloma.
Edwards SK; Moore CR; Liu Y; Grewal S; Covey LR; Xie P
BMC Cancer; 2013 Oct; 13():481. PubMed ID: 24131623
[TBL] [Abstract][Full Text] [Related]
65. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
66. Critical B-lymphoid cell intrinsic role of endogenous MCL-1 in c-MYC-induced lymphomagenesis.
Grabow S; Kelly GL; Delbridge AR; Kelly PN; Bouillet P; Adams JM; Strasser A
Cell Death Dis; 2016 Mar; 7(3):e2132. PubMed ID: 26962682
[TBL] [Abstract][Full Text] [Related]
67. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice.
Kelly PN; Grabow S; Delbridge AR; Strasser A; Adams JM
Blood; 2011 Dec; 118(24):6380-6. PubMed ID: 21998213
[TBL] [Abstract][Full Text] [Related]
68. Anti-apoptotic A1 is not essential for lymphoma development in Eµ-Myc mice but helps sustain transplanted Eµ-Myc tumour cells.
Mensink M; Anstee NS; Robati M; Schenk RL; Herold MJ; Cory S; Vandenberg CJ
Cell Death Differ; 2018 Mar; 25(4):797-808. PubMed ID: 29339775
[TBL] [Abstract][Full Text] [Related]
69. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
[TBL] [Abstract][Full Text] [Related]
70. Transient stabilization, rather than inhibition, of MYC amplifies extrinsic apoptosis and therapeutic responses in refractory B-cell lymphoma.
Harrington CT; Sotillo E; Robert A; Hayer KE; Bogusz AM; Psathas J; Yu D; Taylor D; Dang CV; Klein PS; Hogarty MD; Geoerger B; El-Deiry WS; Wiels J; Thomas-Tikhonenko A
Leukemia; 2019 Oct; 33(10):2429-2441. PubMed ID: 30914792
[TBL] [Abstract][Full Text] [Related]
71. A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells.
Li Z; Van Calcar S; Qu C; Cavenee WK; Zhang MQ; Ren B
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8164-9. PubMed ID: 12808131
[TBL] [Abstract][Full Text] [Related]
72. Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc.
D'Artista L; Bisso A; Piontini A; Doni M; Verrecchia A; Kress TR; Morelli MJ; Del Sal G; Amati B; Campaner S
Oncotarget; 2016 Apr; 7(16):21786-98. PubMed ID: 26943576
[TBL] [Abstract][Full Text] [Related]
73. IgH enhancer deregulated expression of L-myc: abnormal T lymphocyte development and T cell lymphomagenesis.
Möröy T; Fisher P; Guidos C; Ma A; Zimmerman K; Tesfaye A; DePinho R; Weissman I; Alt FW
EMBO J; 1990 Nov; 9(11):3659-66. PubMed ID: 2120050
[TBL] [Abstract][Full Text] [Related]
74. Loss of PRDM11 promotes MYC-driven lymphomagenesis.
Fog CK; Asmar F; Côme C; Jensen KT; Johansen JV; Kheir TB; Jacobsen L; Friis C; Louw A; Rosgaard L; Øbro NF; Marquart HV; Anthonsen K; Braat AK; van Lohuizen M; Ralfkiaer E; Grønbæk K; Lund AH
Blood; 2015 Feb; 125(8):1272-81. PubMed ID: 25499759
[TBL] [Abstract][Full Text] [Related]
75. Identification of a novel E-box binding pyrrole-imidazole polyamide inhibiting MYC-driven cell proliferation.
Mishra R; Watanabe T; Kimura MT; Koshikawa N; Ikeda M; Uekusa S; Kawashima H; Wang X; Igarashi J; Choudhury D; Grandori C; Kemp CJ; Ohira M; Verma NK; Kobayashi Y; Takeuchi J; Koshinaga T; Nemoto N; Fukuda N; Soma M; Kusafuka T; Fujiwara K; Nagase H
Cancer Sci; 2015 Apr; 106(4):421-9. PubMed ID: 25611295
[TBL] [Abstract][Full Text] [Related]
76. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53.
Kelly GL; Grabow S; Glaser SP; Fitzsimmons L; Aubrey BJ; Okamoto T; Valente LJ; Robati M; Tai L; Fairlie WD; Lee EF; Lindstrom MS; Wiman KG; Huang DC; Bouillet P; Rowe M; Rickinson AB; Herold MJ; Strasser A
Genes Dev; 2014 Jan; 28(1):58-70. PubMed ID: 24395247
[TBL] [Abstract][Full Text] [Related]
77. Activating and sustaining c-Myc by depletion of miR-144/451 gene locus contributes to B-lymphomagenesis.
Ding L; Zhang Y; Han L; Fu L; Mei X; Wang J; Itkow J; Elabid AEI; Pang L; Yu D
Oncogene; 2018 Mar; 37(10):1293-1307. PubMed ID: 29284789
[TBL] [Abstract][Full Text] [Related]
78. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer.
Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M
Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793
[TBL] [Abstract][Full Text] [Related]
79. Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells.
Valente LJ; Aubrey BJ; Herold MJ; Kelly GL; Happo L; Scott CL; Newbold A; Johnstone RW; Huang DC; Vassilev LT; Strasser A
Cell Rep; 2016 Mar; 14(8):1858-66. PubMed ID: 26904937
[TBL] [Abstract][Full Text] [Related]
80. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
